Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyAetna Prolia (denosumab) Precertification Coverage…
    Ask Trek AI about this page
    CurrentAetnaPolicy N/A

    Prolia (denosumab) Injectable Medication Precertification Request — Coverage Criteria

    Customize your policy alerts

    Sign up for all Aetna policy alerts

    Know when Aetna releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Form and clinical data requirements for precertification of Prolia (denosumab) injections for Aetna members, used by prescribers and dispensing providers to request start or continuation of therapy.

    Policy Summary
    PayerAetna
    PolicyProlia (denosumab) Injectable Medication Precertification Request — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete all fields on the two-page precertification request, including patient demographics, prescriber/dispensing information, ICD codes, dose/frequency, and required clinical data.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2 pagesdocument length
    1-866-752-7021Aetna precertification phone
    1-888-267-3277Aetna precertification fax
    requiredclinical info

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Prolia (denosumab)

    Initiation and continuation criteria (form-based)

    Information and clinical criteria requested to establish medical necessity for initiation or continuation of Prolia.

    General requirements: Complete required form fields including administration setting, product dose/frequency, primary and secondary ICD codes, and prescriber/dispensing provider information.

    See Required documentation and Precertification required (documentation module).

    Indication-specific sections captured on form: Form includes indication-specific sections for: breast cancer (adjuvant aromatase inhibitor therapy), glucocorticoid-induced osteoporosis, osteoporosis in men, postmenopausal osteoporosis, and prostate cancer on androgen deprivation therapy.

    Providers must mark the applicable indication section on the form.

    Initiation — required clinical item-set

    • Fracture history and BMD/FRAX: Document history of fragility/osteoporotic vertebral or hip fracture where applicable; record pre-treatment T-score category and pre-treatment FRAX scores for major fracture and hip fracture.T-score: categories (-2.5 or below; between -2.5 and -1; -1 or above); FRAX major >=20% threshold; FRAX hip >=3% threshold.

      Use the form checkboxes to indicate exact values.

    • Glucocorticoid-induced osteoporosis: If glucocorticoid-induced osteoporosis is indicated, document current or planned prednisone-equivalent dose >= 2.5 mg/day for >= 3 months.>= 2.5 mg/day for >= 3 months
    • Prior osteoporosis injectable therapy: For postmenopausal osteoporosis the form asks whether the patient has failed prior injectable osteoporosis therapy (e.g., zoledronic acid, teriparatide, abaloparatide).

      Mark Yes/No on form.

    • Prior bisphosphonate trial or documented contraindication: Indicate whether the patient has had at least a 1-year trial of an oral OR injectable bisphosphonate or document a clinical reason to avoid bisphosphonates.At least a 1-year trial where applicable.

      If avoiding bisphosphonates, providers must indicate reason(s) from form options (e.g., esophageal abnormalities, active upper GI disease, malabsorption, inability to sit/stand for 30–60 minutes, renal insufficiency with creatinine clearance <35 mL/min, history of intolerance, or other).

    Continuation — required clinical item-set

    • Evidence of clinical benefit: Document improvement or stabilization in T-score on bone mass measurement compared with prior measurement and/or no new fractures (e.g., no new fracture seen on radiography).

      Form asks Yes/No for improved/stable T-score and for no new fractures.

    • Duration of therapy and administration source: Indicate length of time patient has been receiving the medication (months) and whether drug was received via samples or manufacturer assistance program.

      Form includes checkbox for sample/patient assistance program and months on therapy.

    • Adverse effects: Report whether the patient has experienced any adverse effects during therapy.

      Form requires Yes/No response.

    Operational note — documentation of bisphosphonate avoidance: If a clinical reason to avoid bisphosphonates is selected, indicate the specific reason from the form's list (e.g., esophageal abnormalities, active upper GI disease, gastrointestinal malabsorption, inability to sit/stand, renal insufficiency with creatinine clearance <35 mL/min, history of intolerance, or other).Creatinine clearance < 35 mL/min where renal insufficiency is claimed.

    Providers must indicate reason(s) on the form; these are documented reasons to avoid bisphosphonates rather than automatic exclusions.

    The precertification form captures clinical reasons why a patient may need to avoid oral bisphosphonates. Providers should document any relevant contraindication or intolerance by selecting the appropriate reason(s) on the form, such as anatomic or functional esophageal abnormalities that impair tablet transit (e.g., achalasia, stricture, dysmotility), active upper gastrointestinal disease (e.g., dysphagia, gastritis, duodenitis, erosive esophagitis, ulcers), or documented or potential gastrointestinal malabsorption (e.g., gastric bypass, celiac disease, Crohn's disease).

    Other form-listed reasons that justify avoiding oral bisphosphonates include inability to stand or sit upright for 30–60 minutes, inability to take the oral bisphosphonate at least 30–60 minutes before first food/drink/medication, renal insufficiency (creatinine clearance < 35 mL/min), a documented history of intolerance to an oral bisphosphonate, or other clinically explained reasons documented in the free-text field.

    For continuation requests the form requires documentation demonstrating ongoing clinical benefit. Specifically, providers must indicate whether the patient has shown benefit by a bone mass measurement with improvement or stabilization in T-score compared with the prior study and whether there have been no new fractures on radiography. The form also requests the duration of therapy and whether any adverse effects have occurred.

    Requests for continued coverage that do not provide the required documentation of benefit (stable or improved T-score, absence of new fractures) or that omit requested continuation fields may not support approval and could lead to denial or a request for additional information.

    Coding and Clinical Thresholds

    Administration CPT codes (provider to supply)CPT
    Administration code(s) (CPT)Field provided to list CPT administration codes
    Diagnosis codes (provider to supply)ICD-10
    Primary ICD CodeField to specify primary ICD diagnosis code
    Secondary ICD CodeField to specify secondary ICD diagnosis code
    Other ICD CodeField to specify other ICD diagnosis codes
    inv-06: Prednisone-equivalent glucocorticoid dose
    Prednisone-equivalent dose>= 2.5 mg/day for >= 3 months
    Documentation requiredForm asks whether patient is currently receiving or will initiate glucocorticoid therapy at this dose and duration
    Applies toGlucocorticoid-induced osteoporosis indication on the form
    inv-07: FRAX major fracture threshold
    FRAX major fracture threshold>= 20%
    Form capturePre-treatment FRAX for any major fracture recorded as less than 20%, greater than or equal to 20%, or unknown
    Applies to indicationsPostmenopausal osteoporosis, osteoporosis in men, and other applicable indications listed on the form
    inv-08: FRAX hip fracture threshold
    FRAX hip fracture threshold>= 3%
    Form capturePre-treatment FRAX for hip fracture recorded as less than 3%, greater than or equal to 3%, or unknown
    Applies to indicationsPostmenopausal osteoporosis, osteoporosis in men, and other applicable indications listed on the form
    inv-09: Very low T-score threshold
    Very low T-score cutoff-3.0 or below
    Form categories include-2.5 or below, between -2.5 and -1, -1 or above, or unknown; very low defined as -3 or below in very-high-risk indicators
    Used to identifyIndicator of very high fracture risk on the form
    inv-10: Creatinine clearance
    Creatinine clearance threshold< 35 mL/min
    Form useListed as a clinical reason to avoid oral bisphosphonates (renal insufficiency: creatinine clearance less than 35 mL/min)
    Applies toAssessment of bisphosphonate contraindication on initiation sections

    Precertification and Documentation Requirements

    Prior Authorization

    Precertification Required

    Precertification is required for requests. Complete all fields on the two‑page Prolia (denosumab) precertification form (patient demographics, prescriber, dispensing provider/administration, product, diagnosis, and full clinical information). Include start or continuation date and signature/date on the acknowledgement. The plan may request additional information or clarification to evaluate requests.

    • Use the Aetna Precertification Notification contacts: Phone 1-866-752-7021 (TTY:711); FAX 1-888-267-3277.
    • For Medicare Advantage Part B, use the Medicare request form as noted on the precertification form.
    Documentation Required

    Prior Bisphosphonate / Injectable Therapy Information

    Document prior bisphosphonate and injectable osteoporosis therapy history clearly on the form. Indicate whether the patient has had at least a 1‑year trial of an oral OR injectable bisphosphonate, and if not, provide reason(s) for avoidance or intolerance. For postmenopausal osteoporosis document prior failure or intolerance to injectable therapies where applicable (e.g., zoledronic acid [Reclast], teriparatide [Forteo, Bonsity], abaloparatide [Tymlos]). Include durations (e.g., at least 1 year for bisphosphonates) and specifics of intolerance or contraindication (esophageal abnormalities, active upper GI disease, malabsorption, inability to take/tolerate dosing requirements, renal insufficiency with CrCl <35 mL/min, documented history of intolerance).

    • Checkboxes on the form: Has the patient had at least a 1‑year trial of an oral or injectable bisphosphonate? (Yes/No).
    • If Yes — document dates and agent(s) used and response.
    • If No or if avoiding bisphosphonate — indicate clinical reason(s) (select from provided options or explain): anatomic/functional esophageal abnormalities, active upper GI problems, gastrointestinal malabsorption, inability to sit/stand upright for dosing, inability to take oral bisphosphonate before food, renal insufficiency (CrCl <35 mL/min), history of intolerance, or other (explain).
    • For postmenopausal patients: indicate prior failure or intolerance to injectable osteoporosis therapy where applicable and document agent(s) and dates.
    Denial Risk

    Fraud and Information Requests

    Fraud warning and acknowledgement must be signed and dated by the requester. The form states that knowingly filing false or misleading information is a fraudulent insurance act subject to criminal and civil penalties. Maintain and submit complete, accurate clinical documentation; be prepared to provide additional records if requested.

    • Request Completed By (Signature Required) and Date — must be present.
    • Failure to provide complete and truthful information may result in denial and referral for fraud investigation.

    Background

    Prolia (denosumab) is indicated on the form for treatment of osteoporosis across common clinical scenarios captured for precertification: postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis (prednisone-equivalent dose >= 2.5 mg/day for >= 3 months is queried), and osteoporosis related to cancer therapy (e.g., adjuvant aromatase inhibitor therapy or androgen deprivation therapy). The form collects baseline measures used to establish risk and need for therapy, including pre-treatment T-scores, FRAX scores (major fracture and hip fracture thresholds), fracture history, prior bisphosphonate or injectable osteoporosis therapy, and documented reasons to avoid bisphosphonates.

    The continuation section of the form requires evidence of ongoing benefit (improvement or stabilization in T-score or no new fractures) and length of prior therapy, and asks providers to report any adverse effects while on therapy.

    Definitions and High-Risk Indicators

    inv-16: Very high fracture risk
    Advanced ageListed as an indicator of very high fracture risk on the form
    FrailtyListed as an indicator of very high fracture risk on the form
    Current or planned glucocorticoid useIncluded as an indicator of very high fracture risk (see glucocorticoid dose threshold)
    Very low T-scoresExplicitly noted as -3 or below as an indicator of very high fracture risk
    Increased fall riskListed as an indicator of very high fracture risk on the form
    Policy Summary
    PayerAetna
    PolicyProlia (denosumab) Injectable Medication Precertification Request — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete all fields on the two-page precertification request, including patient demographics, prescriber/dispensing information, ICD codes, dose/frequency, and required clinical data.
    SourceLink
    On This Page
    Coverage Criteria for Prolia (denosumab)Coding and Clinical ThresholdsPrecertification and Documentation RequirementsBackgroundDefinitions and High-Risk Indicators